Skip to main content
. 2023 Jan 27;24(3):2464. doi: 10.3390/ijms24032464

Figure 3.

Figure 3

GLP1-R expression in patients with metabolic dysfunction and its correlation with dopamine receptors expression. Expression of GLP1R did not alter between groups of obese patients with different grades for glucose and insulin dysmetabolism (B). GLP1R expression correlates with decreased expression of DRD1 and DRD4 in all groups of insulin resistance patients ((C,I); (E,K)) but not in insulin-sensitive patients ((F,H)). GLP1R expression did not correlate with DRD2 for all groups of patients (D,G,J). Bars represent the median ± interquartile range. Kruskal-Wallis was used to assess differences between groups (IS: insulin-sensitivity normoglycemic, IR-NG: Insulin resistance normoglycemic, IR-PD: Insulin resistance pre-diabetic, and IR-D: Insulin resistance diabetic patients). Spearman correlations were used to assess the expression of GLP1R correlation with dopamine receptors expression. Levels of significance: 1 symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 0.001.